This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
BELLUS (BLU) Completes Enrollment in Two Mid-Stage Studies
by Zacks Equity Research
BELLUS (BLU) completes enrollment in the mid-stage studies for refractory chronic cough and chronic pruritus associated with atopic dermatitis.
U.S. Household Net Worth Hits Record High in Q2: 5 Picks
by Nalak Das
We have narrowed down our search to five large-cap stocks have given double-digit returns in the past three months. These are: CLR, DAR, REGN, ORLY and MOS.
AbCellera (ABCL), Everest to Co-Develop New Antibody Therapies
by Zacks Equity Research
AbCellera (ABCL) partners with China-based Everest Medicines to expand the latter???s pipeline across multiple indications.
Enlivex (ENLV) Begins Phase IIb COVID-19 Study on Cell Therapy
by Zacks Equity Research
Enlivex (ENLV) doses the first patient in a phase IIb study evaluating its cell therapy, Allocetra, in severe and critical COVID-19 patients with acute respiratory distress syndrome.
Can Regeneron (REGN) Stock Continue to Grow Earnings?
by Zacks Equity Research
If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider Regeneron (REGN).
4 Top Biotech Stocks to Watch as Economic Recovery Picks Up Pace
by Ekta Bagri
New drug approvals and focus on coronavirus treatments should maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position REGN, MRNA, VRTX, and HZNP well amid the economic recovery.
bluebird (BLUE) Submits BLA for Gene-Therapy to Treat Thalassemia
by Zacks Equity Research
bluebird (BLUE) files BLA with the FDA for its gene therapy, betibeglogene autotemcel (beti-cel), in patients with transfusion-dependent ¿¿-thalassemia.
Lilly (LLY) to Supply COVID Cocktail Drug to EU Countries
by Zacks Equity Research
Elli Lilly (LLY) is set to supply 220,000 doses of its COVID-19 antibody cocktail to European Union member nations, following approval.
5 Stocks With High ROE as Markets Await Fed Tapering Outlook
by Supriyo Bose
OneMain Holdings (OMF), KLA Corporation (KLAC), Bunge Limited (BG), CBRE Group, (CBRE) and Regeneron Pharmaceuticals (REGN) are some of the stocks with high ROE to buy as markets await Fed tapering clarity.
Incyte (INCY) Ruxolitinib Cream Wins FDA Nod for Atopic Dermatitis
by Zacks Equity Research
Incyte (INCY) obtains FDA approval for the cream formulation of ruxolitinib for the treatment of mild to moderate atopic dermatitis.
AbbVie (ABBV) Files for Skyrizi in Crohn's Disease With FDA
by Zacks Equity Research
AbbVie (ABBV) submits a regulatory application in the United States, seeking approval for Skyrizi in Crohn's disease.
Biogen's (BIIB) Lucentis BioSimilar Byooviz Gets FDA Approval
by Zacks Equity Research
Biogen (BIIB) announces the approval of Byooviz, its biosimilar referencing Roche's Lucentis, by the FDA.
AstraZeneca (AZN) Up on Enhertu, Imfinzi Cancer Data at ESMO
by Zacks Equity Research
AstraZeneca's (AZN) Enhertu reduces the risk of disease progression by 72% in HER2-positive metastatic breast cancer. Imfinzi plus chemotherapy triples patient survival at three years in ES-SCLC.
Verrica (VRCA) Gets CRL From the FDA for Skin Disease Drug
by Zacks Equity Research
Verrica (VRCA) suffers a setback yet again as the FDA issues a CRL for its lead product candidate VP-102. Consequently, shares are trading down.
Regeneron (REGN) Stock Moves -1.69%: What You Should Know
by Zacks Equity Research
Regeneron (REGN) closed at $640.89 in the latest trading session, marking a -1.69% move from the prior day.
Roche (RHHBY) Lung Cancer Drug Gets Positive CHMP Opinion
by Zacks Equity Research
Roche (RHHBY) gets a positive CHMP opinion for Gavreto for the treatment of adult patients with RET fusion-positive advanced NSCLC.
Bristol Myers' (BMY) Opdivo Combo for Gastric Cancer Gets CHMP Nod
by Zacks Equity Research
Bristol Myers' (BMY) Opdivo, in combination with chemotherapy, gets positive CHMP recommendation by the EMA for treating adults with gastric cancer, among others.
Biogen's (BIIB) MS Drug, Vumerity, Gets Positive CHMP Opinion
by Zacks Equity Research
The CHMP gives a positive opinion on, and recommends granting marketing authorization to Biogen's (BIIB) Vumerity for the treatment of adults with relapsing-remitting multiple sclerosis.
Glaxo's (GSK) Nucala Gets CHMP Nod for 3 Diseases in Europe
by Zacks Equity Research
Glaxo (GSK) is seeking approval of Nucala for hypereosinophilic syndrome, eosinophilic granulomatosis with polyangiitis) and chronic rhinosinusitis with nasal polyps in Europe
Biogen (BIIB) Reports Mixed Data From Neuropathy Pain Study
by Zacks Equity Research
Biogen (BIIB) reports mixed data from the phase II study evaluating its non-opioid pain candidate vixotrigine for treating small fiber neuropathy.
Lilly (LLY) Gets FDA Nod for Expanded Use of COVID Cocktail
by Zacks Equity Research
FDA revises Lilly's (LLY) EUA for COVID-19 antibody cocktail, bamlanivimab and etesevimab, for post-exposure prophylaxis for COVID-19.
Regeneron, Lilly Get New COVID Drug Deals From Government
by Zacks Equity Research
Regeneron (REGN) is set to supply an additional 1.4 million doses of its antibody cocktail for COVID-19, REGEN-COV while Lilly (LLY) will supply 388,000 doses of its COVID-19 antibody medicine, etesevimab to the U.S. government.
Aerie (AERI) Announces Mixed Data From Dry Eye Disease Study
by Zacks Equity Research
Aerie Pharmaceuticals (AERI) reports mixed data from the phase IIb study evaluating AR-15512 for treating dry eye disease. Resultantly, the stock declines in after-market trading on Sep 15.
Company News for Sep 16, 2021
by Zacks Equity Research
Companies in The News Are: MSFT,AAPL,REGN,YUMC
Has Regeneron Pharmaceuticals (REGN) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (REGN) Outperforming Other Medical Stocks This Year?